Sign in or Register   Sign in or Register
  |  

Mouse Anti-ACP5 Recombinant Antibody (V2-179372) (CBMAB-A0674-YC)

Provided herein is a Mouse monoclonal antibody against Human Acid Phosphatase 5, Tartrate Resistant. The antibody can be used for immunoassay techniques, such as ELISA, FC, WB.
See all ACP5 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
V2-179372
Antibody Isotype
IgG
Application
ELISA, FC, WB

Basic Information

Immunogen
Recombinant protein corresponding to aa 221-325 from human ACP5 expressed in E. coli
Specificity
Human
Antibody Isotype
IgG
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:500-1:2,000
FC1:200-1:400
ELISA1:10,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid in PBS, 0.05% sodium azide, 0.5% protein stabilizer
Buffer
PBS, 0.5% protein stabilizer
Preservative
0.05% sodium azide
Concentration
Batch dependent
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Acid Phosphatase 5, Tartrate Resistant
Introduction
ACP5 is an iron containing glycoprotein which catalyzes the conversion of orthophosphoric monoester to alcohol and orthophosphate. It is the most basic of the acid phosphatases and is the only form not inhibited by L(+)-tartrate.
Entrez Gene ID
54
UniProt ID
P13686
Alternative Names
Acid Phosphatase 5, Tartrate Resistant; Tartrate-Resistant Acid ATPase; Human Purple Acid Phosphatase; EC 3.1.3.2; TrATPase; Tartrate-Resistant Acid Phosphatase Type 5; Tartrate-Resistant Acid Phosphatase 5a; Tartrate-Resistant Acid Phosphatase 5b;
Function
Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias.
Biological Process
Bone resorption
Ossification
Riboflavin metabolic process
Cellular Location
Lysosome
Involvement in disease
Spondyloenchondrodysplasia with immune dysregulation (SPENCDI): A disease characterized by vertebral and metaphyseal dysplasia, spasticity with cerebral calcifications, and strong predisposition to autoimmune diseases. The skeletal dysplasia is characterized by radiolucent and irregular spondylar and metaphyseal lesions that represent islands of chondroid tissue within bone.

Shakya, M., Raizada, S., Yadav, R., & Singh, P. (2021). Computational Fine-Tuning of Functional Single Nucleotide Polymorphisms Associated with ACP5 Gene to Characterize Missense Mutations Running Title: SNP Analysis of ACP5 Gene.

Hu, Y., Yu, J., Wang, Q., Zhang, L., Chen, X., Cao, Y., ... & Xiong, W. (2020). Tartrate-resistant acid phosphatase 5/ACP5 interacts with p53 to control the expression of SMAD3 in lung adenocarcinoma. Molecular Therapy-Oncolytics, 16, 272-288.

Bai, X., He, C., Fu, B., Kong, X., Bu, J., Zhu, K., ... & Ni, B. (2020). microRNA-877 contributes to decreased non-small cell lung cancer cell growth via the PI3K/AKT pathway by targeting tartrate resistant acid phosphatase 5 activity. Cell Cycle, 19(23), 3260-3276.

Hu, Y., Yu, J., Wang, Q., Zhou, Q., Deng, Y., Liu, J., ... & Wang, Y. (2020). Tartrate-resistant acid phosphatase 5 serves as a viable target against pulmonary fibrosis by modulating β-catenin signaling.

Ramesh, J., Parthasarathy, L. K., Janckila, A. J., Begum, F., Murugan, R., Murthy, B. P., ... & Venugopal, B. (2020). Characterisation of ACP5 missense mutations encoding tartrate-resistant acid phosphatase associated with spondyloenchondrodysplasia. PloS one, 15(3), e0230052.

Huang, Y., Wang, L., Mao, Y., & Nan, G. (2019). Long noncoding RNA-H19 contributes to atherosclerosis and induces ischemic stroke via the upregulation of acid phosphatase 5. Frontiers in neurology, 10, 32.

He, C., Bai, X., Li, Y., Sun, H., Kong, X., Fu, B., ... & Xu, S. (2019). Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5. Cell Cycle, 18(23), 3404-3419.

Reithmeier, A., Lundbäck, T., Haraldsson, M., Frank, M., Ek‐Rylander, B., Nyholm, P. G., ... & Andersson, G. (2018). Identification of inhibitors of Tartrate‐resistant acid phosphatase (TRAP/ACP 5) activity by small‐molecule screening. Chemical biology & drug design, 92(1), 1255-1271.

Gao, Y. L., Liu, M. R., Yang, S. X., Dong, Y. J., & Tan, X. F. (2018). Prognostic significance of ACP5 expression in patients with lung adenocarcinoma. The clinical respiratory journal, 12(3), 1100-1105.

Ren, X., Shan, W. H., Wei, L. L., Gong, C. C., & Pei, D. S. (2018). ACP5: Its structure, distribution, regulation and novel functions. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 18(8), 1082-1090.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-ACP5 Recombinant Antibody (V2-179372)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare